Abstract
Mass spectrometric approaches have been used to determine various peptide hormones in sports drug testing. While insulin-like growth factor-1 (IGF-1) and its synthetic analogs are qualitatively and/or quantitatively measured by liquid chromatography–tandem mass spectrometry after immunoaffinity purification, methods of uncovering doping rule violations with illegal applications of human growth hormone (hGH) have not yet been established using mass spectrometry-based assays. However, substantial information on the heterogeneity of hGH, splice variants and post-translational modifications with respective locations as elucidated by mass spectrometry are of utmost importance for improving currently employed immunological procedures.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bredehöft M, Schänzer W, Thevis M (2008) Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom 22:477–485
Gam LH, Tham SY, Latiff A (2003) Immunoaffinity extraction and tandem mass spectrometric analysis of human chorionic gonadotropin in doping analysis. J Chromatogr B Analyt Technol Biomed Life Sci 792:187–196
Gasthuys M, Alves S, Fenaille F, Tabet JC (2004) Simple identification of a cross-linked hemoglobin by tandem mass spectrometry in human serum. Anal Chem 76:6628–6634
Gasthuys M, Alves S, Tabet J (2005) N-terminal adducts of bovine hemoglobin with glutaraldehyde in a hemoglobin-based oxygen carrier. Anal Chem 77:3372–3378
Giorgianni F, Beranova-Giorgianni S, Desiderio DM (2004) Identification and characterization of phosphorylated proteins in the human pituitary. Proteomics 4:587–598
Goebel C, Alma C, Howe C, Kazlauskas R, Trout G (2005) Methodologies for detection of hemoglobin-based oxygen carriers. J Chromatogr Sci 43:39–46
Hepner F, Cszasar E, Roitinger E, Lubec G (2005) Mass spectrometrical analysis of recombinant human growth hormone (Genotropin(R)) reveals amino acid substitutions in 2% of the expressed protein. Proteome Sci 3:1
Kohler M, Püschel K, Schänzer W, Thevis M (2007) Mass spectrometric identification of human pituitary growth hormone variants. In: Schänzer W, Geyer H, Gotzmann A, Mareck U (eds) Recent advances in doping analysis. Sport & Buch Strauß, Cologne, pp 21–30
Kohler M, Püschel K, Sakharov D, Tonevitskiy A, Schänzer W, Thevis M (2008) Detection of recombinant growth hormone in human plasma by a 2D-PAGE method. Electrophoresis 29:4495–4502
Kohler M, Thomas A, Püschel K, Schänzer W, Thevis M (2009) Identification of human pituitary growth hormone variants by mass spectrometry. J Proteome Res 8:1071–1076
Nelson RW, Nedelkov D, Tubbs KA, Kiernan UA (2004) Quantitative mass spectrometric immunoassay of insulin like growth factor 1. J Proteome Res 3:851–855
Popot MA, Bobin S, Bonnaire Y, Delahaut PH, Closset J (2001) IGF-I plasma concentrations in non-treated horses and horses administered with methionyl equine somatotropin. Res Vet Sci 71:167–173
Popot MA, Woolfitt AR, Garcia P, Tabet JC (2008) Determination of IGF-I in horse plasma by LC electrospray ionisation mass spectrometry. Anal Bioanal Chem 390:1843–1852
Thevis M, Schänzer W (2007) Current role of LC–MS(/MS) in doping control. Anal Bioanal Chem 388:1351–1358
Thevis M, Ogorzalek-Loo RR, Loo JA, Schänzer W (2003) Doping control analysis of bovine hemoglobin-based oxygen therapeutics in human plasma by LC-electrospray ionization-MS/MS. Anal Chem 75:3287–3293
Thevis M, Thomas A, Delahaut P, Bosseloir A, Schänzer W (2005) Qualitative determination of synthetic analogues of insulin in human plasma by immunoaffinity purification and liquid chromatography-tandem mass spectrometry for doping control purposes. Anal Chem 77:3579–3585
Thevis M, Bredehöft M, Geyer H, Kamber M, Delahaut P, Schänzer W (2006a) Determination of Synacthen in human plasma using immunoaffinity purification and liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 20:3551–3556
Thevis M, Thomas A, Delahaut P, Bosseloir A, Schänzer W (2006b) Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography-tandem mass spectrometry. Anal Chem 78:1897–1903
Thevis M, Thomas A, Schänzer W (2008) Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrom Rev 27:35–50
Thomas A, Thevis M, Delahaut P, Bosseloir A, Schänzer W (2007) Mass spectrometric identification of degradation products of insulin and its long-acting analogues in human urine for doping control purposes. Anal Chem 79:2518–2524
Thomas A, Geyer H, Kamber M, Schanzer W, Thevis M (2008) Mass spectrometric determination of gonadotrophin-releasing hormone (GnRH) in human urine for doping control purposes by means of LC-ESI-MS/MS. J Mass Spectrom 43:908–915
Zhan X, Giorgianni F, Desiderio DM (2005) Proteomics analysis of growth hormone isoforms in the human pituitary. Proteomics 5:1228–1241
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Thevis, M., Bredehöft, M., Kohler, M., Schänzer, W. (2010). Mass Spectrometry-Based Analysis of IGF-1 and hGH. In: Thieme, D., Hemmersbach, P. (eds) Doping in Sports: Biochemical Principles, Effects and Analysis. Handbook of Experimental Pharmacology, vol 195. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79088-4_9
Download citation
DOI: https://doi.org/10.1007/978-3-540-79088-4_9
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-79087-7
Online ISBN: 978-3-540-79088-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)